CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 104 enrolled
Drug / intervention
carboplatin +8 moredrug
Likely dose
Carboplatin, etoposide, ifosfamide, and thiotepa given IV as neoadjuvant chemotherapy; specific doses not stated in protocol summaryAI-extracted
Key inclusion· 12
  • Histologically confirmed intracranial NGGCT of one of the following types: endodermal sinus tumor, embryonal carcinoma, choriocarcinoma, immature teratoma, teratoma with malignant transformation, or mixed germ cell tumor
  • Histologically confirmed germinoma with serum or CSF beta-HCG >50 mIU/mL or serum or CSF AFP >10 ng/mL or above institutional norm
  • Histologically unconfirmed pineal and/or suprasellar tumors with serum or CSF beta-HCG >50 mIU/mL or AFP >10 ng/mL or above institutional norm
  • Age 3 to 24 years at diagnosis
Key exclusion· 7
  • Patients with normal AFP and beta-HCG <50 mIU/mL without histologic diagnosis of NGGCT
  • Pure germinoma without elevation of tumor markers
  • Patients in status epilepticus or coma
  • Pregnancy or nursing

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00047320
NCT00047320Phase 2Completed

A Phase II Study To Assess The Ability Of Neoadjuvant Chemotherapy Plus/Minus Second Look Surgery To Eliminate All Measurable Disease Prior To Radiotherapy For NGGCT

Children's Oncology Group·interventional·Posted Jan 27, 2003·Updated Feb 14, 2018

In Brief

A Phase 2 clinical trial evaluating carboplatin, etoposide, and 7 other interventions for Brain Tumor and 2 related conditions. Completed, enrolled 104 participants across 106 sites in 5 countries.

Detailed Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it is no longer present by conventional imaging and tumor markers from serum and cerebrospinal fluid. Radiation therapy uses high-energy x-rays to damage tumor cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Combining different types of therapy may kill more tumor cells. PURPOSE: This Phase II trial is studying how well neoadjuvant chemotherapy with or without surgery and with or without high dose chemotherapy and peripheral stem cell transplantation, can increase response rates prior to radiation therapy and increase progression free and overall surviving patients with newly diagnosed intracranial germ cell tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Canada, New Zealand, Switzerland, United States

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartJan 1, 2004
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 23.4 years ago

Interventions

carboplatindrug

Given IV

etoposidedrug

Given IV

ifosfamidedrug

Given IV

thiotepadrug

Given IV

adjuvant therapyprocedure

conventional surgeryprocedure

neoadjuvant therapyprocedure

peripheral blood stem cell transplantationprocedure

radiation therapyradiation

craniospinal irradiation